CrushSCI.com
145.2Average days
137Median days
43Fastest days
318Longest days
1352025 publications

Paper Review Records

All Paper Review Records

19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

137 days

Neoantigen in cancer immunotherapy: mechanism, therapeutic strategies and future perspectives

Authors
Aditya Raj; Zuber Khan; Mumtaz; Sidharth Mehan; Tapan Lamba; Niyati Pandoh; Keerti DayalShow moreShow less
Affiliations
1. ISF College of Pharmacy (An Autonomous College); 2. ISF College of Pharmacy (Affiliated to IK Gujral Punjab Technical University, Jalandhar); 3. School of Pharmaceutical Education and ResearchShow moreShow less
Source PDF DOI Publisher page
128 days

The role of artificial intelligence in predicting immunotherapy treatment outcomes based on gut microbiota composition in cancer patients: a meta-analysis

Authors
Leen Alhassan; Bassel Alrabadi; Suhel F. Batarseh; Yousef Alghzawi; Natalie Bandak; Aseel Badwan; Hadeel Al kayedShow moreShow less
Affiliations
1. Jordan University of Science and Technology; 2. University of Jordan; 3. WellStar Cobb HospitalShow moreShow less
Source PDF DOI Publisher page
65 days

Making dietary modification in the immunotherapy Era: from mechanistic evidence to practical implementation

Authors
Parham Habibzadeh; Drew Hurd; Diwakar DavarShow moreShow less
Affiliations
1. University of Pittsburgh Medical Center; 2. University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center; 3. University of PittsburghShow moreShow less
Source PDF DOI Publisher page
129 days

Cost-effectiveness analysis of Nivolumab plus Ipilimumab versus Nivolumab monotherapy in previously treated metastatic colorectal cancer patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) in China

Authors
Xiaohong Zhu; Xu Yang; Tong LiuShow moreShow less
Affiliations
1. Harbin Medical University Cancer HospitalShow moreShow less
Source PDF DOI Publisher page
43 days

Safety and tolerability of a new intravenous immunoglobulin 10% in patients with primary immunodeficiency

Authors
Roberto Crea; Elena Perez; Chaim M. RoifmanShow moreShow less
Affiliations
1. Kedrion S.p.A; 2. Allergy Associates of the Palm Beaches; 3. Hospital for Sick ChildrenShow moreShow less
Source PDF DOI Publisher page
257 days

Impact of sublingual immunotherapy with dust mite drops on ECP, TARC, VCAM-1 inflammatory status in patients with allergic rhinitis

Authors
Bangyu Deng; Yunxia Zhao; Jisheng LiuShow moreShow less
Affiliations
1. The Affiliated Suzhou Hospital of Nanjing Medical University; 2. Suzhou Jinji Lake Health Service Center; 3. The First Affiliated Hospital of Soochow UniversityShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.